The global heart valves market size valued USD 6.86 billion in 2020 and expected to reach USD 16.02 billion by 2027, at a CAGR of 11.9% during the forecast period 2021-2027. Heart valves are the medical devices which are used in the replacement of defective heart valve. Heart valves are majorly 2 types, they are biological or tissue and mechanical heart valves. Biological heart valves are made up of various tissues such as porcine, bovine and human tissues. Heart valves made from human tissues are known as homografts or allografts. The major advantage of tissue valves over mechanical valve is mechanical heart valves can cause bleeding and increase the chances of reoperations in geriatric people. Since the use of tissue heart valves in people of this age group lowers the risks of bleeding. Physicians are increasingly opting for this method as it able to reduce the use of oral anticoagulation drugs for the management of bleeding complications. Heart valves market is growing at a significant CAGR due to increase in geriatric population, and increase in the prevalence of heart valve diseases. Global heart valves market is increasing due to rise in the prevalence of cardiac disorders. The most commonly adopted strategies by industry players include new product launches with technological innovations, acquisitions & mergers, agreements, and collaborations to capture significant Heart valves market share. They acquire other companies to enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. Acquisition of other companies allows vendors access to the product portfolio of the acquired company. For instance, in December 2012, Edwards Lifesciences Corporation and Cook Biotech Incorporated, have collaborated into a technology licensing and supply agreements for the development of tissue-engineered heart valves and related cardiovascular implants.